Table 1.
Patient and disease characteristics.
| Retrospective patient data set | Prospective, newly-diagnosed cGvHD | |||
|---|---|---|---|---|
| All patients | cGvHDa | Non-cGvHDa | ||
| Characteristics | n = 63 | n = 35 | n = 28 | n = 7 |
| Age, years | ||||
| Median (and range) | 50 (19–64) | 45 (19–62) | 51 (26–64) | 44 (31–58) |
| Gender, no. (%) | ||||
| Male | 31 (49.2) | 15 (42.9) | 16 (57.1) | 6 (85.7) |
| Female | 32 (50.8) | 20 (57.1) | 12 (42.9) | 1 (13.3) |
| Diagnosis - no. (%) | ||||
| Lymphoid | 27 (41.3) | 14 (40.0) | 17 (60.7) | 4 (57.1) |
| Prior autologous transplantation | 4 | 3 | 1 | 1 |
| Myeloid | 34 (54.0) | 23 (65.7) | 12 (42.9) | 3 (42.9)) |
| Anemia (Aplastic Anemia or Diamond-Blackfan Anemia) | 2 (3.2) | 1 (2.9) | 1 (3.6) | 0 |
| Donor - no. (%) | ||||
| Sibling | 41 (65.1) | 22 (62.9) | 19 (67.9) | 2 (28.6) |
| Unrelated | 22 (34.9) | 13 (37.1) | 9 (32.1) | 5 (71.4) |
| Conditioning - no. (%) | ||||
| Reduced-intensity conditioning | 25 (39.7) | 9 (25.7) | 16 (57.1) | 2 (28.6) |
| Myeloablative | 38 (60.3) | 26 (74.3) | 12 (42.9) | 5 (71.4) |
| Acute GvHD - no. (%) | ||||
| None | 46 (73.0) | 20 (57.1) | 26 (92.9) | 2 (28.6) |
| Yes | 17 (27.0) | 15 (42.9) | 2 (7.1) | 5 (71.4) |
| Grade 1 | 1 | 1 | 0 | 2 |
| Grade 2 | 5 | 4 | 1 | 3 |
| Grade 3 | 9 | 8 | 1 | 0 |
| Grade 4 | 2 | 2 | 0 | 0 |
a
2 patients with a history of mild severity cGvHD who were weaned from immunosuppressive medications yet maintained on 5 mg every-other-day of prednisone for >180 days at the time of sample acquisition were considered non-GvHD.